Mechanism of Endocrine Therapy Resistance in Breast Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 1 May 2026
Special Issue Editors
Interests: Pharmacology and biology of breast cancer including mechanisms of endocrine-resistance including protein kinase C (PKC) signaling as a mechanism of tamoxifen-resistant breast cancer; Breast cancer and lung cancer Patient-Derived Xenografts (PDXs); Development of the Selective human Estrogen Receptor Agonists (ShERPAs) TTC-352 in Phase I Clinical Trial for metastatic breast cancer
Interests: ..
Special Issue Information
Dear Colleagues,
Approximately 75-80% of all breast tumors express the estrogen receptor (ER+) and respond to drugs that target the ER or the ER signaling pathway. These includes adjuvant tamoxifen, used primarily in premenopausal patients, and aromatase inhibitors (AIs), including letrozole, anastrozole, and exemestane, used primarily in postmenopausal patients. Unfortunately, as many as 50% of ER+ breast cancer patients will develop metastatic or advanced localized disease, wherein most tumors will remain ER+ but develop adaptive resistance to tamoxifen and/or AIs. The first-line treatment of ER+ metastatic breast cancer (MBC) includes the use of AIs or selective estrogen receptor degraders (SERDs), including fulvestrant, elacestrant, and, more recently, imlunestrant (specifically in ESR1 mutant tumors). SERDs can be used alone but are most often used in combination with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib). For third-line treatment, chemotherapy is commonly used in patients lacking any actionable mutations and may include antibody-drug conjugates (ADCs) such as sacituzumab govitecan (Trodelvy). For this Special Issue, “Mechanisms behind Endocrine Therapy Resistance in Breast Cancer”, we welcome original articles and reviews sharing new findings on topics including novel mechanisms behind endocrine resistance, predictive biomarkers, innovative pathological approaches, new drug targets, and novel therapeutics, as well as clinical updates. We believe that the discovery of new therapeutic approaches will allow patients to receive treatment earlier and will result in improved outcomes and the avoidance of cytotoxic chemotherapy.
Prof. Dr. Debra A. Tonetti
Dr. Clodia Osipo
Prof. Dr. Ruth M. O'Regan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- estrogen receptor, endocrine resistance, mechanism of action
- predictive biomarkers
- signal transduction
- novel therapeutics
- drug sequencing
- drug targets
- pathological findings.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
